{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Thioctic+Acid&page=2",
    "query": {
      "intervention": "Thioctic Acid",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Thioctic+Acid&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T03:01:33.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00795262",
      "title": "Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Quinapril (Accupril) plus Alpha Lipoic Acid",
          "type": "DRUG"
        },
        {
          "name": "accupril, placebo",
          "type": "DRUG"
        },
        {
          "name": "accupril, alpha lipoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InVasc Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 23,
      "start_date": "2008-07",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2011-05-05",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "Tucker, Georgia",
      "locations": [
        {
          "city": "Tucker",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795262"
    },
    {
      "nct_id": "NCT02613572",
      "title": "Alpha Lipoic Acid in Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "alpha lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 68,
      "start_date": "2015-11",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 5,
      "location_summary": "Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02613572"
    },
    {
      "nct_id": "NCT01398423",
      "title": "INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Active Control",
          "type": "DRUG"
        },
        {
          "name": "INV-144",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InVasc Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 88,
      "start_date": "2011-06",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 19,
      "location_summary": "Garden Grove, California • La Mesa, California • Northridge, California + 15 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01398423"
    },
    {
      "nct_id": "NCT00237718",
      "title": "Provision of Antioxidant Therapy in Hemodialysis (PATH) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End-stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Alpha, gamma, beta, and delta (mixed) tocopherols",
          "type": "DRUG"
        },
        {
          "name": "Alpha lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 385,
      "start_date": "2006-04",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2012-01-11",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00237718"
    },
    {
      "nct_id": "NCT01355952",
      "title": "An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Weight Loss",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Alpha Lipoic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2011-05",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2015-11-05",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01355952"
    },
    {
      "nct_id": "NCT00845156",
      "title": "Alpha Lipoic Acid and Insulin Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Alpha Lipoic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "20 Years to 60 Years"
      },
      "enrollment_count": 68,
      "start_date": "2008-01",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845156"
    },
    {
      "nct_id": "NCT04916327",
      "title": "Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Vascular Diseases"
      ],
      "interventions": [
        {
          "name": "Antioxidant",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 720,
      "start_date": "2021-08-23",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04916327"
    },
    {
      "nct_id": "NCT03370159",
      "title": "CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "6,8-Bis(benzylthio)octanoic Acid",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-06",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370159"
    },
    {
      "nct_id": "NCT00477607",
      "title": "Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ototoxicity",
        "Unspecified Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "alpha-lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Audiology",
          "type": "BEHAVIORAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "BIOLOGICAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2007-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-03-07",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477607"
    },
    {
      "nct_id": "NCT03493841",
      "title": "Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Progressive Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis",
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Alpha Lipoic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebecca Spain",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-06-08",
      "completion_date": "2019-01-25",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-09-27T03:01:33.734Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03493841"
    }
  ]
}